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Abstract
Tardive dyskinesia (TD) is associated with polymorphisms of the dopamine
D3, serotonin 2A and 2C receptors (DRD3, HTR2A and HTR2C, respectively).
This study investigated the possible relationship between TD and the
polymorphisms Ser9Gly (DRD3), 102T>C (HTR2A), −1438G>A(HTR2A) and
Cys23Ser (HTR2C) in African-Caribbean inpatients. One hundred and
twenty-six patients under chronic antipsychotic treatment were
genotyped. The assessment of TD was carried out with the abnormal
involuntary movement scale (AIMS). The relationships between the
carriership of the least frequent alleles and the respective orofaciolingual
dyskinesia (TDof) (sum of the items 1–4 of the AIMS), limb-truncal
dyskinesia (TDlt) (sum of items 5–7 of the AIMS) and TD (sum of items
1–7 of the AIMS) were analyzed with ANCOVA, comparing means with age
as a covariate and stratification for carriers and non-carriers of the
mutations. In addition, we conducted pre-planned t-tests to compare
AIMS values of carriers of the combinations of alleles versus the
corresponding non-carriers. In the study population, females with 9Ser
carriership exhibited higher AIMS values than non-carriers. Male subjects
with 9Ser carriership in combination with 23Ser or −1438A carriership
exhibited higher AIMS values. In male patients also, the combination of
23Ser and −1438A carriership increased TD. The study clearly shows that
the African-Carribean population differs from the Caucasian population
with regard to the association of TD with the polymorphisms studied and
suggests that the association of TD with the studied polymorphisms of the
5-HT2C and probably of the 5-HT2A receptor are the result of a changed
susceptibility of the patients, independent of the action of the
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Introduction
Up to 75% of patients chronically exposed to typical antipsy-
chotics may develop antipsychotic-induced movement
disorders such as tardive dyskinesia (TD), tardive dystonia,
parkinsonism and akathisia (Gerlach, 1999; Gerlach, 2002).
Drug-induced movement disorders can produce physical
handicaps; however, more often patients feel embarrassed
about the abnormal movements. TD is often a reason for
non-compliance of medications and increases the risk of psy-
chotic relapse (Gerlach, 2002; Strejilevich, et al., 2005). TD is
potentially irreversible and has a prevalence of approximately
30% in patients chronically exposed to antipsychotics (Kane,
et al., 1988; Glazer, 2000). Several risk factors such as age,
female gender, Negroid race and co-morbidity with akathisia
have been reported to predispose to TD (Kane, et al., 1988;
Morgenstern and Glazer, 1993; van Harten, et al., 1998;
Glazer, 2000; Wonodi, et al., 2004). However, this only
accounts for a small amount of the variance in the occurrence
of TD (Jeste and Caligiuri, 1993; Basile, et al., 2002) and
hereditary predisposition may play a role as well (Weinhold,
et al., 1981; Yassa and Ananth, 1981; Youssef, et al., 1989;
Rosengarten, et al., 1994; Muller, et al., 2001).
The dopamine D3 receptor (DRD3) is involved in TD in an
experimental primate model (Malik, et al., 2004) and its phar-
macogenetics has been investigated in relation to TD [for
review see Bakker et al. (2006)] and other forms of movement
disorders (Eichhammer, et al., 2000; Mihara, et al., 2002;
Chong, et al., 2003; Coffey, et al., 2005).
The serotonergic system interacts with the dopaminergic
system and therefore 5-HT2A and 5-HT2C receptors (HTR2A
and HTR2C, respectively) may be responsible for some of the
dyskinetic effects of antipsychotics (Segman, et al., 2000).
Indeed, genetic variations of HTR2A (Basile, et al., 2001; Seg-
man, et al., 2001; Tan, et al., 2001; Herken, et al., 2003; Lat-
tuada, et al., 2004; Lerer, et al., 2005) and HTR2C (Segman,
et al., 2000; Zhang, et al., 2002; Werge, et al., 2003; Reynolds,
et al., 2005) genes have been studied in relation to
antipsychotic-induced movement disorders or TD. However,
since the 102T>C polymorphism of the 5-HT 2A receptor is
non-functional, we also genotyped for the –1438G>A polymor-
phism, which is functional and in complete linkage disequilib-
rium with the 102T>C polymorphism (Spurlock, et al., 1998;
Kouzmenko, et al., 1999; Segman, et al., 2001; Ellingrod,
et al., 2003)
Ethnicity can be an important pharmacogenetic determi-
nant (Frackiewicz, et al., 1997) and a relative two-fold increase
in risk for developing TD has been found in African-American
patients versus white Americans (Morgenstern and Glazer,
1993). As far as we know, there are no pharmacogenetic studies
of TD in African-Caribbeans.
In the present study, we hypothesised that the carriership of
a variant allele of the polymorphisms of Ser9Gly (DRD3),
−1438G>A (HTR2A) and Cys23Ser (HTR2C) would affect
the severity of orofaciolingual dyskinesia (TDof) and limb-
truncal dyskinesia (TDlt). Furthermore, we hypothesised that
there might be additive effects of the polymorphisms.
Methods and Materials
Subjects
In this study, we used data from predominantly African-
Caribbean inpatients of the Psychiatric Hospital of the Dutch
Antilles in Curaçao. The results of this epidemiological study
have previously been reported (van Harten, et al., 1996). One
hundred and twenty-six subjects (99 males, mean age 47.5
years; 27 females, mean age 55.4 years) met the inclusion crite-
ria, which has been described elsewhere (van Harten, et al.,
1996), gave oral informed consent after full explanation of the
study, and provided DNA for genotyping. The study protocol
was approved by the local Curaçao review board. Four trained
raters assessed the patients and each patient was examined in
the same way by two raters simultaneously. After the examina-
tion, a joint decision was reached regarding the presence or
absence of each EPS and, if present, the ratings were estab-
lished by consensus. Furthermore, two medical doctors,
blinded for the existence of antipsychotic-induced movement
disorders, extracted clinical and demographic data from the
patients’ medical files.
TD was assessed with the abnormal involuntary movement
scale (AIMS), which includes items for TDof and TDlt (Amer-
ican Psychiatric Association – Task force on tardive dyskinesia,
1992). For the measurement of TDof and TDlt, we summed
items 1–4 and items 5–7 of the AIMS score, respectively. Fur-
thermore, we calculated TDsum, which is the sum of both
TDof and TDlt scores (AIMS 1–7).
Medication
Two junior medical doctors, who were not aware of the exis-
tence of movement disorders in the subjects, assessed patients’
medical files for information on the type, dose, and duration of
the antipsychotic treatment(van Harten, et al., 1998). The dose
of the antipsychotic medication was converted into chlorprom-
azine equivalents (CPZEQ), as described by Davis (Davis,
1976).
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DNA genotyping
Genomic DNA was extracted from whole-blood samples to
which EDTA was added, as described previously (Miller,
et al., 1988). Genotyping for Ser9Gly (DRD3), 102T>C
(HTR2A) and Cys23Ser (HTR2C) was performed using stan-
dard polymerase chain reaction (PCR) protocols in combina-
tion with restriction fragment length polymorphism (RFLP)
analysis, as described in the literature (Lannfelt, et al., 1992;
Warren, Jr. et al., 1993; Ebstein, et al., 1997).
Genotyping for the polymorphic −1438G>A (HTR2A) was
conducted by a fluorogenic 5′-exonuclease TaqMan® assay,
ordered from Applied Biosystems as an Assay-On-Demand
(C___8695278_10).
We labelled subjects heterozygous, hemizygous or homozy-
gous for a particular allele as carriers of that allele, because of
the sample size of our study population. It should, however, be
emphasised that no assumptions were made regarding the
inheritance mode.
Statistics
Pearson correlation was applied to study the correlations
between age and TDof, TDlt and TDsum. ANCOVA analyses
were applied to compare the mean AIMS values in carriers and
in non-carriers of 9Ser-, −1438A-, and 23Ser-alleles using age
as a covariate. In addition, we conducted pre-planned t-tests to
compare AIMS values of carriers of the following combina-
tions of alleles versus the corresponding non-carriers. The com-
binations studied were 9Ser+23Ser (DRD3 and HTR2C),
9Ser+-1438A (DRD3 and HTR2A) and 23Ser+-1438A
(HTR2C and HTR2A). P-values < 0.05 were regarded as
significant.
Departure from Hardy–Weinberg Equilibrium was calcu-
lated for all polymorphisms except those of the X-
chromosomal HTR2C gene. An online tool was applied for the
chi-square goodness-of-fit test (http://www.kursus.kvl.dk/
shares/vetgen/_Popgen/genetik/applets/kitest.htm).
Since our analyses were replications of previously published
findings in other populations, hypothesis-driven corrections for
multiple testing were not applied.
Results
Demographic and clinical features of the subjects
One hundred and twenty-six African-Caribbean subjects (99
males and 27 females) met the inclusion criteria. Table 1
shows the distribution (mean ± standard deviation) of age
(years) and the current (mg/day chlorpromazine equivalents)
and lifetime dose of antipsychotics (kg chlorpromazine equiva-
lents). Table 1 also presents the various AIMS values for the
total sample and those for each gender.
Genotype distribution and carriership frequencies
The distribution of the different genotypes is shown in Table 2.
All genotypes were in Hardy–Weinberg equilibrium. Carrier-
ship is assessed as being carrier of the variant alleles defined
as the alleles of the least frequent homozygotes. Since all car-
riers except for 2 of the 102T allele were also carrier of the
−1438A allele (data not shown), further analyses were only
made with the functional polymorphic –1438G>A.
The effects of antipsychotic medications
The majority (n = 114) of the patients used antipsychotics on
the day of examination. Of these 114 patients, only 7 patients
were using an atypical antipsychotic as monotherapy (risperi-
done in all cases). In addition to those 7 patients, there was also
1 patient who used risperidone, however, in combination with
a classical neuroleptic.
All patients used antipsychotics for at least 245 days. The
lifetime dose of antipsychotics (CPZLIFE) in males amounted
to 3.90 ± 3.21 and in females to 4.00 ± 3.21 kg chlorpromazine
equivalents (mean ± SD).
The daily use of antipsychotics (as expressed by CPZ) as
well as the lifetime exposure to antipsychotics (as expressed
by CPZLIFE) did not differ significantly between the different
classes analyzed (data not shown).
Table 1 The distribution of the age, daily use of antipsychotics (mg/day chlorpromazine equivalents, CPZ), life-time dose of antipsychotics (kg
chlorpromazine equivalents, CPZLIFE) and the AIMS values
Male (99) Female (27) All (126)
Age (years) 47.5 ± 13.0 55.4 ± 13.3 49.2 ± 13.4
CPZ (mg chlorpromzaine equivalents/day) 692.4 ± 676.8 662.5 ± 953.8 686.0 ± 740.6
CPZLIFE (kg chlorpromazine equivalents)* 3.90 ± 3.21 4.00 ± 3.21 3.92 ± 3.19
Orofaciolingual AIMS (TDof) 2.9 ± 3.5 3.1 ± 3.5 2.9 ± 3.5
Limb-truncal AIMS (TDlt) 0.9 ± 1.4 0.7 ± 1.3 0.8 ± 1.4
AIMS 1-7 (TDsum) 3.7 ± 4.5 3.9 ± 4.0 3.8 ± 4.4
*Data available from only 93 patients (72 males + 21 females).
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The effects of the age on TDof, TDlt and TDsum
There was no significant correlation between age and TDlt
in both males and females. However, TDsum correlated
significantly with age in females (Pearson’s correlation
coefficient = 0.46; P = 0.017). Furthermore, there was a posi-
tive correlation between age and TDof in males, which, how-
ever, did not reach statistical significance, (P = 0.058) and in
females (Pearson’s correlation coefficient = 0.46; P = 0.016).
On the basis of these findings, we chose to make corrections
for age effects in ANCOVA analysis.
The effects of allele carrierships on TDof values
After adjustment was made for age, there were no statistically
significant differences between the TDof values of carriers or
non-carriers of the 9Ser allele of the Ser9Gly polymorphism
(DRD3), of the −1438A allele of the −1438G>A polymor-
phism (HTR2A) and of the 23Ser allele of the Cys23/Ser23
polymorphism (HTR2C) if analyzed separately. However,
male patients carrying both 9Ser and 23Ser alleles had signifi-
cantly higher TDof-values than those without these two alleles
(3.26 and 1.30, respectively; P = 0.051).
Subjects carrying both 9Ser and −1438A alleles also exhib-
ited higher AIMS values when compared with the non-carriers
of these alleles. However, the difference was not siginificant
(1.76 and 3.51 for non-carriers and carriers, respectively;
P = 0.062).
Furthermore, those carrying 23Ser and −1438A alleles
simultaneously exhibited significantly higher AIMS orofacio-
lingual values than the corresponding non-carriers (4.55 and
2.39, respectively; P = 0.026).
After adjustment for age in female patients, carriers of the
9Ser, −1438A, and 23Ser alleles (DRD3, HTR2A and HTR2C
genes, respectively) exhibited higher TDof values than those in
the corresponding non-carriers. However, of these three genetic
variations, only carriers of the 9Ser allele of the Ser9Gly poly-
morphism (DRD3) had significantly higher TDof values than
non-carriers (4.18 versus 1.66; P = 0.042).
Carriership of the −1438A allele or the 23Ser allele on top
of carriership of the 9Ser allele did not lead to an additional
statistically significant increase in TDof values.
Moreover, the combined carriership of the −1438A and the
23Ser alleles did not lead to a statistical significant increase in
TDof. An overview of these data is given in Table 3.
The effects of allele carrierships on TDlt values
After adjustment was made for age, there were no statistically
significant differences in both genders between the TDlt values
of carriers or those of non-carriers of the 9Ser allele of the
Ser9Gly polymorphism of the DRD3 gene, of the −1438A
allele of the −1438G>A polymorphism of the HTR2A gene
and of the Ser23 allele of the Cys23Ser polymorphism of the
HTR2C gene if analyzed separately.
However, males carrying both the 9Ser and the 23Ser alleles
exhibited higher TDlt values than the corresponding non-
carriers, with the difference being almost statistically significant
(1.20 versus 0.41 AIMS points; P = 0.057), but not for patients
carrying both the 9Ser and −1438A alleles or both the 23Ser
and −1438A alleles.
In females, there were no statistically significant differences
between TDlt values in patients carrying either one of the fol-
lowing allelic combinations 9Ser/23Ser, 9Ser/-1438A, or 23Ser/
−1438A. An overview of these data is given in Table 3.
Table 2 Genotype distribution, χ2-values for Hardy–Weinberg equilibrium, as well as the number (n) and percentage of allele-positive subjects
(carriers) in African-Caribbean patients
Genotype % of the total sample
(n)







Gly9/Gly9 39.7 (50) 0.004 Non-carriers of 9Ser allele 39.7 (50) 39.4 (39) 40.7 (11)
Gly9/Ser9 46.8 (59) Carriers of the 9Ser allele 60.3 (76) 60.6 (60) 59.3 (16)
Ser9/ Ser9 13.5 (17)
HTR2C Cys23Ser
Cys23/Cys23 61.9 (78) — Non-carriers of 23Ser allele 61.9 (78) 70.7 (70) 29.6 (8)
Cys23/Ser23 11.1 (14) Carriers of the 23Ser allele 38.1 (48) 29.3 (29) 70.4 (19)
Ser23/Ser23 27.0 (34)
HTR2A −1438G>A
−1438G/G 44.8 (56) 0.127 Non-carriers of −1438A allele 44.8 (56) 47.5 (47) 34.6 (9)
−1438G/A 43.2 (54) Carriers of the −1438A allele 55.2 (69) 52.5 (52) 65.4 (17)
−1438A/A 12.0 (15)
HTR2C is localised on the X-chromosome; males can therefore only be hemizygous for the Cys23Ser polymorphism. For males, the hemizygosities for the
23Cys and the 23Ser alleles are denoted as Cys23/Cys23 and Ser23/Ser23, respectively.
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The effects of allele carrierships on TDsum values
When analyzed separately, carriership of 9Ser (DRD3),
−1438A (HTR2A) and 23Ser (HTR2C) alleles were not accom-
panied by significantly different age-adjusted TDsum values
both in males and in females.
However, in males, statistically significant higher TDsum
values were found in male patients carrying the combinations:
9Ser and 23Ser alleles (4.45 and 1.71 for carriers and non-
carriers of this combination, respectively; P = 0.036), 9Ser and
−1438A alleles (4.49 and 2.09 for carriers and non-carriers of
this combination, respectively; P = 0.048), and 23Ser and
−1438A alleles (5.77 and 3.08 for carriers and non-carriers of
this combination, respectively; P = 0.034).
In females, we observed no statistically significant differ-
ences in TDsum values between carriers and non-carriers of
the 9Ser/23Ser or the 23Ser/−1438A allelic combinations. How-
ever, female carriers of the 9Ser/−1438A allelic combination
exhibited significantly higher TDsum values than the corre-
sponding non-carriers (5.63 versus 0.23, respectively;
P = 0.032). An overview of these data is given in Table 3.
Discussion
Several studies have reported the relationship between TD and
Ser9Gly, 102T>C, and Cys23Ser polymorphisms of dopamine
D3, serotonin 2A and 2C receptors, respectively, in different
populations (Segman, et al., 2000; Liao, et al., 2001; Lerer,
et al., 2002; Chong, et al., 2003; Lerer, et al., 2005). This is
the first published pharmacogenetic study of TD in predomi-
nantly African-Caribbeans.
The present study suggests that the pharmacogenetic asso-
ciations of TD in African-Caribbeans are different from those
in Caucasians, specifically regarding polymorphism of dopa-
mine D3 (Ser9Gly polymorphism), serotonin 2A (102T>C and
1438G>A polymorphisms) and 2C receptors (Cys23Ser poly-
morphism). Furthermore, our data suggest that the effects of
the genotypic studies might be clinically significant.
The antipsychotics used have a low affinity to 5HT2C and to
5HT2A receptors. Therefore, our data suggest that in the popu-
lation studied, the association of TD with Cys23Ser polymor-
phism of the 5HT2C receptor and probably also with the –
1438G>A polymorphism of the 5HT2A receptor is likely to be
independent of the direct action of the antipsychotics on these
receptors.
The association observed is probably the result of a distinct
endogenous susceptibility of the patients. In other words, these
patients seem to have a higher susceptibility for TD, indepen-
dent of the antipsychotic used. Notably, African-Americans in
the Yale study, which also included white Americans, displayed
an almost doubled relative risk for TD (Morgenstern and
Glazer, 1993; Eastham, et al., 1996). Most of the patients
investigated in this study were African-Caribbeans from the
Netherlands Antilles (Curaçao). African-Caribbeans have eth-
nic roots similar to those of native Africans (Page, 1997).
Table 3 An overview of the effects of the carriership of polymorphisms on TDof, TDlt and TDsum scores
Genetic variation TDof TDlt TDsum
Males
9Ser/23Ser combination
Carriers (N = 19)
Non-carriers (N = 28)
3.26 vs 1.30; P = 0.051 1.20 vs 0.41; P = 0.057 4.45 vs 1.71; P = 0.036
9Ser/−1438A combination
Carriers (N = 36)
Non-carriers (N = 22)
3.51 vs 1.76; P = 0.062 0.98 vs 0.33; P = 0.082 4.49 vs 2.09 ; P = 0.048
23Ser/−1438A combination
Carriers (N = 19)
Non-carriers (N = 37)
4.55 vs 2.39; P = 0.026 1.22 vs 0.69; P = 0.182 5.77 vs 3.08; P = 0.034
Females
9Ser allele carriership
Carriers (N = 16)
Non-carriers (N = 11)
4.17 vs 1.66; P = 0.042 0.39 vs 1.16; P = 0.140 4.56 vs 2.81; P = 0.223
9Ser/23Ser combination
Carriers (N = 12)
Non-carriers (N = 4)
4.46 vs 1.98; P = 0.178 0.56 vs 0.47; P = 0.901 5.02 vs 2.45; P = 0.244
9Ser/−1438A combination
Carriers (N = 9)
Non-carriers (N = 3)
5.34 vs 0.21; P = 0.015 0.29 vs 0.03; P = 0.753 5.63 vs 0.23; P = 0.032
23Ser/−1438A combination
Carriers (N = 14)
Non-carriers (N = 4)
3.62 vs 1.34; P = 0.222 0.97 vs 0; P = 0.208 4.59 vs 1.30; P = 0.125
TD values are presented for carriers versus non-carriers with the corresponding P values. See text for further details.
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The data support a gender-specific analysis, although strati-
fied analysis reduces the power of the study by lowering the
number of patients in each group. Since it has been advocated
that TDof and TDlt must be considered as two distinct pheno-
types (Lerer, et al., 2005), we analyzed these forms of TD sep-
arately. However in our limited study population, we did not
find different genetic effects except for the fact that the effects
did not reach statistical significance for TDlt.
Lerer et al. (2002) summarised data obtained from 780
patients, whereas Bakker et al. (2006) analyzed the data of
695 patients with TD and 915 without TD. Both concluded
that TD was significantly associated with the 9Gly allele carrier
status, also when controlling for age and gender. However, it
seems that the effect of Ser9Gly is opposite in direction in our
African-Caribbean sample. In females, 9Ser carriership was
associated with higher AIMS scores. Furthermore, in males
9Ser carriership combined with either 23Ser or –1438A carrier-
ship increased AIMS scores. Also, in the Chinese population,
Ser9/Ser9 (Lerer et al., 2005) was found to be associated with
TD; however, no gender effect was described. In addition,
Lerer et al. (2002) have also reported an overrepresentation of
the 9Ser alelle in TD patients in their Vienna subsample.
Lerer et al. (2005) performed a combined analysis of a large
multicentre patient sample and found an association between
TDlt, but not TDof, and the 102T>C polymorphism of the
5HT2A receptor, with an increasing risk for C-allele carriers
in older, but not in younger patients. In addition to the
102T>C polymorphism, Segman et al. (2001) studied the –
1438G>A polymorphism and found an excess of both 102C
and –1438G alleles in patients with TDlt.
Since the 102T>C polymorphism is non-functional and is in
linkage disequilibrium with the –1438G>A polymorphism, we
analyzed our data with the former polymorphism. However, in
our African-Caribbean population, the –1438A carriers (whose
carriership was fully associated with carriership of 102T allele)
if combined with 9Ser or 23Ser carriership showed higher TDof
scores in men only in the whole age group. In females, the
effect of the –1438G>A polymorphism could not be demon-
strated. However, the size of the female population in our
study is a limitation. The effects of the –1438G>A polymor-
phism were comparable between TDof and TDlt, but did not
reach statistical significance in the latter.
Since the effects of Ser9Gly, -1438G>A and Cys23Ser poly-
morphisms on the susceptibility for TD vary in different ethnic
groups, it might be speculated that polymorphisms other than
these polymorphisms confer the susceptibility for TD. In fact,
these hypothetical key polymorphisms for TD in our popula-
tion might be inherited together with (linkage disequilibrium)
the polymorphisms we studied.
For the Cys23Ser polymorphism of the 5-HT2C-receptor,
Segman et al. (2000) described an excess of 23Ser alleles in
TDof cases only in females. For TDof, our data are so far in
accordance with the study of Segman et al. (2000) that 23Ser
carriership (HTR2C) in combination with 9Ser carriership
(DRD3) increases the magnitude (by approximately 2 AIMS
points) of the effect ; however, this is observed only in male
patients. In females, we found no statistically significant effects,
but this may result from the low number of female patients (27
versus 55 in the study of Segman et al. (2000)). The additivity
of the effects of the DRD3 and HTR2C polymorphisms in our
male patients is therefore similar to what has been reported by
Segman et al. (2000). However, in our population, the 9Ser car-
riership – but not 9Gly carriership – showed higher TDof
scores.
This study of African-Caribbeans shows for the first time
that this population appears to show different associations
between TD and the Ser9Gly polymorphism of the D3 recep-
tor, −1438G>A polymorphism of the 5-HT2A-receptor. For
the Cys23Ser polymorphism of the 5-HT2C receptor, predomi-
nantly a different gender effect compared with that described
by Segman et al. (2000) was observed, although both studies
have limted sample sizes.
Since the effects of Ser9Gly, −1438G>A and Cys23Ser
polymorphisms on the susceptibility for TD vary in different
ethnic groups, it might be speculated that polymorphisms
other than these polymorphisms confer the susceptibility for
TD. In fact, these hypothetical key polymorphisms for TD in
our population might be inherited together with (linkage dis-
equilibrium) the polymorphisms we studied. It is well known
that the extent of linkage disequilibria varies with ethnicity
and therefore in other populations the key polymorphisms
may be inherited together with other polymorphisms.
Furthermore, the effects of the polymorphisms of the 5-
HT2C and probably also the 5-HT2A receptors observed in
this study in patients using neuroleptics, agents with low bind-
ing affinities for 5-HT2C and high binding affinities for 5-HT2A
receptors, seems to indicate that there is possibly an intrinsic
change in the sensitivity of the patient rather than a drug-
specific effect. Independent of the theoretical explanation, the
results of this study might assist in the future development of
pharmacogenetic testing for predicting TD in African-
Caribbean schizophrenic patients.
Because of the small sample size, the results of the present
study should be considered as preliminary and require confir-
mation based on the study of larger samples, which, however,
especially for this African-Carribean population with its
restricted size might be difficult.
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